Santhera Pharma

Santhera is extending the exclusive distribution agreement with Biomedica to Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan, under which Biomedica will distribute AGAMREE (Vamorolone) in these markets for the treatment of Duchenne muscular dystrophy in patients aged two years and older. Santhera will retain a percentage share of net sales according to the original agreement. An estimated 2,000 DMD patients live in the five countries, for whom AGAMREE could expand previously limited local treatment options. » More on finanzen.net

Santhera has received orphan-drug designation and a priority review for the drug Agamree to treat Duchenne muscular dystrophy in South Korea. This can accelerate the approval process and market access for Agamree in South Korea. » More on finanzen.net

At the ordinary general meeting in Pratteln, Santhera shareholders overwhelmingly approved all motions put forward by the board. The annual report, the 2025 statutory and consolidated financial statements, and the discharge of the board of directors and executive management were approved; participating shareholders represented 4,838,464 shares (31.31%). A change to the articles increased the conditional share capital for the employee participation plan by CHF 46,500 to CHF 118,272.10. Re-elections and one new election to the board were confirmed, and the remuneration report as well as the proposed remunerations for the board and executive management were ratified. » More on finanzen.net